Since GLP-1 receptor agonists (GLP-1RAs) have anti-inflammatory and pulmoprotective effects, they may effectively manage ALI/ARDS and hyperinflammation in Covid-19 (Belančić et al. 2021). This evidence concerns the gene GLP1R and acute respiratory distress syndrome.